Comment on: Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study

被引：0
|
作者：
Bravo Urbieta, Joaquin [1 ,2 ]
Aleman Belando, Sergio [1 ]
机构：
[1] Hosp Gen Univ Jose Maria Morales Meseguer, Internal Med Dept, Infect Dis Unit, Ave Marques Velez S-N, Murcia 30008, Murcia, Spain
[2] Univ Murcia, Dept Internal Med, Fac Med, Hlth Sci Campus,Avda Buenavista 32, El Palmar 30120, Murcia, Spain
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2023年 / 78卷 / 11期
关键词：
D O I：
10.1093/jac/dkad294
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：2780 / 2782
页数：3
相关论文
共 50 条
  • [1] Comment on: Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study
    Giacomelli, Andrea
    Cossu, Maria Vittoria
    Moschese, Davide
    Gervasoni, Cristina
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (12) : 3009 - 3010
  • [2] Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study
    Perfezou, Pascale
    Hall, Nolwenn
    Duthe, Jean-Charles
    Abdi, Basma
    Seang, Sophie
    Arvieux, Cedric
    Lamaury, Isabelle
    Menard, Amelie
    Marcelin, Anne-Genevieve
    Katlama, Christine
    Palich, Romain
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (08) : 1929 - 1933
  • [3] Doravirine plus lamivudine (DOR/3TC) two-drug regimen as a maintenance antiretroviral therapy in controlled HIV-infected patients
    Perfezou, P.
    Hall, N.
    Duthe, J.
    Abdi, B.
    Seang, S.
    Marcelin, A.
    Katlama, C.
    Palich, R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 94 - 94
  • [4] Doravirine plus dolutegravir two-drug regimen as a maintenance ART: Results from a French cohort study
    Robineau, O.
    Palich, R.
    Allevena, C.
    Hentzien, M.
    Becker, A.
    Genet-Villeger, C.
    Hocqueloux, L.
    Duvivier, C.
    HIV MEDICINE, 2023, 24 : 185 - 185
  • [5] Doravirine plus raltegravir (DOR/RAL) two-drug regimen (2-DR) as a maintenance antiretroviral therapy in virally suppressed people living with HIV (PLWH): results of the international randomized DORAL trial
    Palich, Romain
    Castagna, Antonella
    Allavena, Clotilde
    Antinori, Andrea
    Canetti, Diana
    Tiraboschi, Juan
    Duvivier, Claudine
    Martinez, Esteban
    Domingo, Pere
    Barkat, Salima
    Dudoit, Yasmine
    Beniguel, Lydie
    Peytavin, Gilles
    Soulie, Cathia
    Marcelin, Anne-Genevieve
    Assoumou, Lambert
    Katlama, Christine
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 49 - 49
  • [6] A two-drug regimen for antiretroviral therapy
    Kroidl, Arne
    Eberle, Joseph
    LANCET, 2019, 393 (10167): : 106 - 108
  • [7] Durability of two-drug antiretroviral regimens as maintenance therapy in people living with HIV and reasons for switch to a three-drug regimen: A real-life cohort study
    Bontemps, E.
    Meybeck, A.
    Diarra, A.
    Tetart, M.
    Derdour, V.
    Degrendel, M.
    Bocket, L.
    Alidjinou, E. K.
    Robineau, O.
    HIV MEDICINE, 2023, 24 : 142 - 142
  • [8] Two-drug therapy with dolutegravir plus lamivudine in an adult HIV service
    Farrugia, J.
    Pan, D.
    Stephenson, I.
    HIV MEDICINE, 2020, 21 : 19 - 19
  • [9] Perspectives on the Barrier to Resistance for Dolutegravir plus Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
    Boffito, Marta
    Waters, Laura
    Cahn, Pedro
    Paredes, Roger
    Koteff, Justin
    Van Wyk, Jean
    Vincent, Tia
    Demarest, James
    Adkison, Kimberly
    Quercia, Romina
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2020, 36 (01) : 13 - 18
  • [10] Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment
    Cattaneo, Dario
    Capetti, Amedeo
    Rizzardini, Giuliano
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (03) : 245 - 252
12345